Health & bio

Survodutide Phase 3 — Average 16.6% Weight Loss

76-week trial shows overwhelming efficacy vs placebo (3.2%).

Primary sources · 1
Healthline
← View the full 2026-04-25 (Sat) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →